Trihexyphenidyl Can Cause or Worsen RLS and Should Be Avoided
Trihexyphenidyl, an anticholinergic medication used for parkinsonism and extrapyramidal symptoms, is not indicated for RLS treatment and may actually induce or exacerbate RLS symptoms through its effects on dopaminergic pathways. 1
Understanding the Association
Trihexyphenidyl is an anticholinergic agent that inhibits the parasympathetic nervous system and is FDA-approved only for parkinsonism and drug-induced extrapyramidal disorders—not for RLS 1. The drug label specifically mentions "restlessness" as a symptom observed in animal toxicity studies at high doses 1, suggesting potential for inducing rather than treating restless symptoms.
Why Trihexyphenidyl is Problematic for RLS
- Drug-induced RLS mechanism: Anticholinergic medications can trigger or worsen RLS through their effects on dopaminergic neurotransmission and other neurotransmitter systems 2
- Risk factors for drug-induced RLS include older age, high medication doses, and simultaneous use of multiple drugs 2
- No evidence base: Trihexyphenidyl is completely absent from the 2025 AASM RLS treatment guidelines, indicating zero evidence for efficacy 3
Recommended Management Approach
If a Patient on Trihexyphenidyl Develops RLS:
- Identify and discontinue the offending agent or reduce its dosage if medically feasible 2
- Assess for other RLS triggers: Check serum ferritin (treat if <200 ng/mL with transferrin saturation <20%), review all medications for RLS-inducing agents (antidepressants, antihistamines, dopamine antagonists) 3, 4
- Initiate evidence-based RLS treatment if symptoms persist after drug withdrawal:
First-Line Pharmacologic Options (Strong Recommendations):
- Gabapentin enacarbil (strongest evidence) 3
- Gabapentin 3
- Pregabalin 3
- IV ferric carboxymaltose if ferritin is appropriate for iron therapy 3
Second-Line Options (Conditional Recommendations):
- Ferrous sulfate with vitamin C for ferritin ≤75 μg/L 3
- Extended-release oxycodone or other opioids for refractory cases 3
- Dipyridamole 3
Critical Caveat About Dopamine Agonists:
The 2025 AASM guidelines now suggest against standard use of dopamine agonists (pramipexole, ropinirole, rotigotine) due to augmentation risk—a paradoxical worsening of RLS symptoms with long-term use 3, 5. These should only be considered for short-term use in highly selected patients who prioritize immediate symptom relief over long-term complications 3.
Common Pitfall to Avoid
Do not confuse drug-induced extrapyramidal symptoms (which trihexyphenidyl treats) with RLS. Akathisia from antipsychotics can mimic RLS but is a distinct condition requiring different management. True RLS has circadian variation (worse at night), occurs during rest/inactivity, and is relieved by movement 3, 6.